A- A A+

Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial. 

Jutras-Aswad D, Le Foll B, Ahamad K, Lim R, Bruneau J, Fischer B, Rehm J, Wild TC, Wood E, Brissette S, Gagnon L, Fikowski J, Ledjiar O, Masse B, Socias ME; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. 

Am J Psychiatry. 2022 Jun 15:appiajp21090964. doi: 10.1176/appi.ajp.21090964. Epub ahead of print. PMID: 35702828.

https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.21090964

Trends and Disparities in Access to Buprenorphine Treatment Following an Opioid-Related Emergency Department Visit Among an Insured Cohort, 2014-2020. 

Stevens MA, Tsai J, Savitz ST, Nath B, Melnick ER, D'Onofrio G, Jeffery MM. 

JAMA Netw Open. 2022 Jun 1;5(6):e2215287. doi: 10.1001/jamanetworkopen.2022.15287. PMID: 35657629.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2792963

Identifying and Characterizing Medical Advice-Seekers on a Social Media Forum for Buprenorphine Use. 

Garcia GP, Dehghanpoor R, Stringfellow EJ, Gupta M, Rochelle J, Mason E, Pujol TA, Jalali MS. 

Int J Environ Res Public Health. 2022 May 22;19(10):6281. doi: 10.3390/ijerph19106281. PMID: 35627818; PMCID: PMC9141384.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9141384/

Patient perspectives on depot buprenorphine treatment for opioid addiction - a qualitative interview study. 

Johnson B, Flensburg OL, Capusan AJ. 

Subst Abuse Treat Prev Policy. 2022 May 25;17(1):40. doi: 10.1186/s13011-022-00474-2. PMID: 35614466; PMCID: PMC9131643.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131643/

Retention rates with monthly depot buprenorphine in general practice in Melbourne, Australia. 

Andrada E, Rodriguez M, Bandalan JH, Dangelo-Kemp D, Johnston L, Wilson H. 

Aust J Gen Pract. 2022 Jun;51(6):447-451. doi: 10.31128/AJGP-07-21-6098. PMID: 35637592.

https://www1.racgp.org.au/ajgp/2022/june/retention-rates-with-monthly-depot-buprenorphine

Association Between Receipt of Antidepressants and Retention in Buprenorphine Treatment for Opioid Use Disorder: A Population-Based Retrospective Cohort Study. 

Zhang K, Jones CM, Compton WM, Guy GP, Evans ME, Volkow ND. 

J Clin Psychiatry. 2022 Apr 27;83(3):21m14001. doi: 10.4088/JCP.21m14001. PMID: 35485928.

Abstract

https://pubmed.ncbi.nlm.nih.gov/35485928/

Effects of Buprenorphine Dose and Therapeutic Engagement on Illicit Opiate Use in Opioid Use Disorder Treatment Trials. 

Bergen AW, Baurley JW, Ervin CM, McMahan CS, Bible J, Stafford RS, Mudumbai SC, Saxon AJ. 

International Journal of Environmental Research and Public Health. 2022; 19(7):4106. doi.org/10.3390/ijerph19074106 

https://www.mdpi.com/1660-4601/19/7/4106/htm

Prehospital Buprenorphine Treatment for Opioid Use Disorder by Paramedics: First Year Results of the EMS Buprenorphine Use Pilot,

H. Gene Hern, Vanessa Lara, David Goldstein, M. Kalmin, S. Kidane, S. Shoptaw, Ori Tzvieli & Andrew A. Herring (2022)

Prehospital Emergency Care, DOI: 10.1080/10903127.2022.2061661

https://www.tandfonline.com/doi/full/10.1080/10903127.2022.2061661

Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use. 

Xu KY, Mintz CM, Presnall N, Bierut LJ, Grucza RA. 

JAMA Netw Open. 2022;5(5):e2211363. doi:10.1001/jamanetworkopen.2022.11363

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2792121

Six-month buprenorphine-naloxone treatment is associated with neurocognitive function improvement in opioid dependence. 

Ghosh A, Mahintamani T, Rana DK, Basu D, Mattoo SK. 

Indian J Psychiatry. 2022 Mar-Apr;64(2):199-208. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_792_21. Epub 2022 Mar 24. PMID: 35494328; PMCID: PMC9045353.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045353/

Non–prescribed buprenorphine preceding treatment intake and clinical outcomes for opioid use disorder

Williams, Arthur Robin et al.

Journal of Substance Abuse Treatment, Volume 0, Issue 0, 108770 

https://www.journalofsubstanceabusetreatment.com/article/S0740-5472(22)00052-6/fulltext

Buprenorphine for High-dose Tramadol Dependence: A Case Report of Successful Outpatient Treatment. 

Mukau L, Wormley K, Tomaszewski C, Ahmad B, Vohra R, Herring AA. 

Clin Pract Cases Emerg Med. 2022 Feb;6(1):71-74. doi: 10.5811/cpcem.2021.12.54602. PMID: 35226854; PMCID: PMC8885221.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885221/

Integrating Buprenorphine Treatment for Opioid Use with Primary Care is Associated with Greater Retention in Treatment. 

Mirer AG, Tiemstra JD, Hammes NE, Cloum HM, LaFavor KJ. 

J Am Board Fam Med. 2022 Jan-Feb;35(1):206-208. doi: 10.3122/jabfm.2022.01.210292. PMID: 35039431.

https://www.jabfm.org/content/35/1/206.long

Experiences and Preferences of Opioid-Use-Disorder Patients Who Switched from Brand to Generic Buprenorphine/Naloxone Films: A Case Series. 

Cedeño E, Cruz A, Cortés J, Melin K, Roman L, Gonzalez A, Duconge J, Santiago D. 

Patient Prefer Adherence. 2022 Jan 11;16:69-78. doi: 10.2147/PPA.S336155. PMID: 35046643; PMCID: PMC8761029.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761029/

Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients. 

Moss LM, Algera MH, Dobbins R, Gray F, Strafford S, Heath A, et al. (2022) 

PLoS ONE 17(1): e0256752. doi.org/10.1371/journal.pone.0256752

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0256752

Buprenorphine Increases HIV-1 Infection In Vitro but Does Not Reactivate HIV-1 from Latency. 

Gornalusse GG, Vojtech LN, Levy CN, Hughes SM, Kim Y, Valdez R, Pandey U, Ochsenbauer C, Astronomo R, McElrath J, Hladik F. 

Viruses. 2021 Jul 27;13(8):1472. doi: 10.3390/v13081472. PMID: 34452338; PMCID: PMC8402857.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402857/

Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. 

Petrakis I, Springer SA, Davis C, Ralevski E, Gu L, Lew R, Hermos J, Nuite M, Gordon AJ, Kosten TR, Nunes EV, Rosenheck R, Saxon AJ, Swift R, Goldberg A, Ringer R, Ferguson R. 

Addict Sci Clin Pract. 2022 Jan 31;17(1):6. doi: 10.1186/s13722-022-00286-6. PMID: 35101115; PMCID: PMC8802273.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802273/

Buprenorphin. Filling the prescription

This article is the first in a series examining the past, present and future of buprenorphine in the treatment of opioid dependence. Buprenorphine is a medication used in opioid substitution treatment (OST), and it has also been used extensively for the management of pain. The surge of buprenorphine prescribing during the COVID-19 pandemic triggered a reflection of its journey, and with the recent introduction of long-acting injectable buprenorphine we question what its future is within drug treatment services. (DDN – Drink and Drug News, UK, Dezember 2021)

https://viewer.joomag.com/ddn-december-2021-december-2021/0873901001638785940/p6?short&

Low- and very low-dose buprenorphine induction: new(ish) uses for an old(ish) medication?. 

Weimer, M.B. and Fiellin, D.A. (2022), 

Addiction. https://doi.org/10.1111/add.15799

https://onlinelibrary.wiley.com/doi/full/10.1111/add.15799

Statement from SAMHSA Leader on FDA’s Drug Safety Alert on Buprenorphine and Risk for Tooth Decay

Today, Miriam Delphin-Rittmon, Ph.D., Assistant Secretary for Mental Health and Substance Use and the leader of the Substance Abuse and Mental Health Services Administration (SAMHSA), released the following statement in response to recent FDA guidance on how to prevent the use of buprenorphine from leading to tooth decay. Buprenorphine and other opioid agonist medications can reduce the saliva production that is important for optimal oral health.

“SAMHSA urges patients and providers to weigh the lifesaving benefits of buprenorphine with this identified risk in making decisions about starting and ongoing use of buprenorphine."

“SAMHSA supports the FDA’s recommendations that simple steps can help reduce the risk of tooth decay in people taking buprenorphine. This includes swishing with water after allowing sublingual and buccal formulations of buprenorphine to completely dissolve and brushing teeth one hour after taking the medication. Other measures can also help maintain healthy teeth and gums, such as twice daily brushing, regular flossing, the regular consumption of water throughout the day, and routine dental checkups.” (Substance Abuse and Mental Health Services Administration (SAMHSA), USA, 13.01.2022)

https://www.samhsa.gov/newsroom/statements/2022/fda-drug-safety-buprenorphine-risk-tooth-decay

Rapid Transition to Buprenorphine in a Patient With Methadone-Related QTc Interval Prolongation. 

Brogdon H, Facer KL, Cox EJ, Carlson RH Jr, Wurzel JF 3rd. 

J Addict Med. 2021 Dec 3. doi: 10.1097/ADM.0000000000000935. Epub ahead of print. PMID: 34864786.

Abstract

https://pubmed.ncbi.nlm.nih.gov/34864786/

Opioid use disorder from poppy seed tea successfully treated with buprenorphine in primary care: a case report. 

Hagan S, Achtmeyer CE, Hood C, Hawkins EJ, Williams EC. 

Addict Sci Clin Pract. 2021 Dec 3;16(1):71. doi: 10.1186/s13722-021-00280-4. PMID: 34861895; PMCID: PMC8641214.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641214/

Buprenorphine Dosage and Urine Quantitative Buprenorphine, Norbuprenorphine, and Creatinine Levels in an Office-Based Opioid Treatment Program. 

Furo H, Schwartz DG, Sullivan RW, Elkin PL. 

Subst Abuse. 2021 Dec 6;15:11782218211061749. doi: 10.1177/11782218211061749. PMID: 34898987; PMCID: PMC8655441.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655441/

Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients-A Critical Review. 

Soyka M. 

Front Pharmacol. 2021 Nov 23;12:718811. doi: 10.3389/fphar.2021.718811. PMID: 34887748; PMCID: PMC8650116.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650116/

"I don't want to take buprenorphine for the rest of my life": Acceptance and Commitment Therapy for a Client Struggling to Reduce Low-Dose Buprenorphine (a Hermeneutic Single-Case Efficacy Design). 

Shepherd K, Pritty B, Tickle A, Moghaddam N. 

Int J Ment Health Addict. 2021 Dec 20:1-24. doi: 10.1007/s11469-021-00729-2. Epub ahead of print. PMID: 34955695; PMCID: PMC8686789.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686789/

Buprenorphine: Drug Safety Communication - FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain 

AUDIENCE: Dentistry, Anesthesiology, Patient, Health Professional, Pharmacy

ISSUE: The FDA is warning that dental problems have been reported with medicines containing buprenorphine that are dissolved in the mouth. The dental problems, including tooth decay, cavities, oral infections, and loss of teeth, can be serious and have been reported even in patients with no history of dental issues. Despite these risks, buprenorphine is an important treatment option for opioid use disorder (OUD) and pain, and the benefits of these medicines clearly outweigh the risks. (FDA – U.S. Food and Drug Administration, USA, 12.01.2022)

https://www.fda.gov/safety/medical-product-safety-information/buprenorphine-drug-safety-communication-fda-warns-about-dental-problems-buprenorphine-medicines

Prolonged-Release Buprenorphine Therapy in Opioid Use Disorder Can Address Stigma and Improve Patient Quality of Life. 

Somaini L, Vecchio S, Corte C, Coppola C, Mahony A, Pitts A, Cutuli M, Orso R, Littlewood R. 

Cureus. 2021 Oct 5;13(10):e18513. doi: 10.7759/cureus.18513. PMID: 34754672; PMCID: PMC8568308.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8568308/

Microdose induction of buprenorphine-naloxone in a patient using high dose methadone: A case report. 

Menard S, Jhawar A. 

Ment Health Clin. 2021 Nov 8;11(6):369-372. doi: 10.9740/mhc.2021.11.369. PMID: 34824962; PMCID: PMC8582770.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582770/

Retention in care for persons with opioid use disorder transitioning from sublingual to injectable buprenorphine. 

Stein MD, VanNoppen D, Herman DS, Anderson BJ, Conti M, Bailey GL. 

J Subst Abuse Treat. 2021 Nov 14:108661. doi: 10.1016/j.jsat.2021.108661. Epub ahead of print. PMID: 34801283.

Abstract

https://pubmed.ncbi.nlm.nih.gov/34801283/

Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. 

Farrell M, Shahbazi J, Byrne M, Grebely J, Lintzeris N, Chambers M, Larance B, Ali R, Nielsen S, Dunlop A, Dore GJ, McDonough M, Montebello M, Nicholas T, Weiss R, Rodgers C, Cook J, Degenhardt L; CoLAB study team. 

Int J Drug Policy. 2021 Nov 1;100:103492. doi: 10.1016/j.drugpo.2021.103492. Epub ahead of print. PMID: 34736130.

https://www.sciencedirect.com/science/article/pii/S0955395921004059

  1. Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial. 
  2. Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. 
  3. Recent advances in the treatment of opioid use disorders-focus on long-acting buprenorphine formulations. 
  4. Trends in and Characteristics of Buprenorphine Misuse Among Adults in the US. 
  5. Recovery capital among people receiving treatment for opioid use disorder with buprenorphine.